ReviewGM crops & food2025
Initiating the commercialization of genetically modified staple crops in China: domestic biotechnological advancements, regulatory milestones, and governance frameworks.
Review in GM crops & food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- From lab to market: industrialization barriers and regulation optimization for new breeding technologies in China.GM crops & food · 2026Article
- Metabolic engineering of cereal lipids: from omega-3 fatty acids to wax esters and pheromones.Advanced biotechnology · 2026Review
- Bibliometric-Based Analysis of Global Trends and Collaborative Networks in Plant Genetic Engineering (1994-2024).Plant biotechnology journal · 2026Review
- Beyond GMOs: transgene-free gene-edited crops for global food security.Frontiers in plant science · 2026Review
- Benefits, concerns, and sustainable alternatives to genetically modified crops from a global and Indian perspective.The plant genome · 2025Review
- The Enhancement of Fungal Disease Resistance in Major Staple Crops Using CRISPR-Cas Technology.Genes · 2025Review
- CRISPR-Cas Gene Editing Technology in Potato.International journal of molecular sciences · 2025Review
Corrections and comments
- Erratum issuedCorrection.2025
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, China's approach to genetically modified (GM) staple crops has been cautious. However, in 2021, China launched its first pilot program for the commercial cultivation of GM food crops and subsequently expanded their cultivation. Previously, the only GM plants cultivated in China were insect-resistant cotton and virus-resistant papaya. The regulatory and policy shifts, from initial research and cautious development to accelerated commercialization, led to significant changes in China's safety-related regulatory framework for genetically modified organism (GMOs). Here, China's progress in GMO research and commercialization over the past three decades is comprehensively analyzed. This review traces the evolution of core regulations governing GMO safety, summarizes the Chinese model of GMO safety governance, and highlights the remaining challenges as commercialization progresses. The goal was to present the international community with a GMO safety governance model reflecting China's characteristics and practices, offering a Chinese solution to balancing GMO commercial adoption with ecological preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.